Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Cerebrospinal fluid α-synuclein levels in Parkinson's disease--changed or unchanged?

Zetterberg H, Petzold M, Magdalinou N.

Eur J Neurol. 2014 Mar;21(3):365-7. doi: 10.1111/ene.12326. Epub 2013 Dec 16. No abstract available.

PMID:
24330157
2.

Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.

van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WD.

Eur J Neurol. 2014 Mar;21(3):388-94. doi: 10.1111/ene.12176. Epub 2013 Apr 30.

PMID:
23631635
3.

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.

Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J.

Brain. 2010 Mar;133(Pt 3):713-26. doi: 10.1093/brain/awq008. Epub 2010 Feb 15.

4.

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.

Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670. Epub 2011 Apr 5.

PMID:
21469206
5.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
6.

Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis.

Parnetti L, Cicognola C, Eusebi P, Chiasserini D.

Biomark Med. 2016;10(1):35-49. doi: 10.2217/bmm.15.107. Epub 2015 Dec 8. Review.

7.

Quantification of α-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease?

Mollenhauer B.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S76-9. doi: 10.1016/S1353-8020(13)70020-8. Review.

PMID:
24262194
8.

Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity.

Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Wang Y, Ginghina C, Liu C, Cain KC, Auinger P, Kang UJ, Jensen PH, Shi M, Zhang J.

Acta Neuropathol Commun. 2015 Jan 31;3:7. doi: 10.1186/s40478-015-0185-3.

9.

Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.

Gao L, Tang H, Nie K, Wang L, Zhao J, Gan R, Huang J, Zhu R, Feng S, Duan Z, Zhang Y, Wang L.

Int J Neurosci. 2015;125(9):645-54. doi: 10.3109/00207454.2014.961454. Epub 2014 Oct 2. Review.

PMID:
25202803
10.

Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.

Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, Dardis A, Deganuto M, De Carlo C, Castrioto A, Balducci C, Paciotti S, Tambasco N, Bembi B, Bonanni L, Onofrj M, Rossi A, Beccari T, El-Agnaf O, Calabresi P.

Mov Disord. 2014 Jul;29(8):1019-27. doi: 10.1002/mds.25772. Epub 2014 Jan 16.

11.

[Alpha-Synuclein in blood and cerebrospinal fluid of patients with alpha-synucleinopathy].

Ono K, Yamada M.

Rinsho Byori. 2014 Mar;62(3):241-5. Review. Japanese.

PMID:
24800499
12.

Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid.

Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollenhauer B.

Methods. 2012 Apr;56(4):514-8. doi: 10.1016/j.ymeth.2012.03.016. Epub 2012 Mar 23. Review.

PMID:
22465793
13.

α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease.

Waragai M, Sekiyama K, Sekigawa A, Takamatsu Y, Fujita M, Hashimoto M.

Int J Mol Sci. 2010 Oct 29;11(11):4257-66. doi: 10.3390/ijms11114257. Review.

14.

Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.

Sako W, Murakami N, Izumi Y, Kaji R.

Mov Disord. 2014 Nov;29(13):1599-605. doi: 10.1002/mds.26036. Epub 2014 Sep 25.

PMID:
25258345
15.

CSF α-synuclein, tau, and amyloid β in Parkinson's disease.

Shi M, Zhang J.

Lancet Neurol. 2011 Aug;10(8):681; author's reply 681-3. doi: 10.1016/S1474-4422(11)70130-2. No abstract available.

PMID:
21777821
16.

CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.

Mondello S, Constantinescu R, Zetterberg H, Andreasson U, Holmberg B, Jeromin A.

Parkinsonism Relat Disord. 2014 Apr;20(4):382-7. doi: 10.1016/j.parkreldis.2014.01.011. Epub 2014 Jan 22.

PMID:
24507721
17.

Is elevated beta-hexosaminidase activity a potential biomarker for Parkinson's disease?

McNeill A.

Mov Disord. 2014 Sep;29(10):1328-9. doi: 10.1002/mds.25972. Epub 2014 Jul 30. No abstract available.

PMID:
25130999
18.

CSF α-synuclein does not differentiate between parkinsonian disorders.

Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM.

Neurobiol Aging. 2012 Feb;33(2):430.e1-3. doi: 10.1016/j.neurobiolaging.2010.12.001. Epub 2011 Jan 13.

19.

Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.

Foulds PG, Yokota O, Thurston A, Davidson Y, Ahmed Z, Holton J, Thompson JC, Akiyama H, Arai T, Hasegawa M, Gerhard A, Allsop D, Mann DM.

Neurobiol Dis. 2012 Jan;45(1):188-95. doi: 10.1016/j.nbd.2011.08.003. Epub 2011 Aug 10.

20.

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.

Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OM.

Biochem Biophys Res Commun. 2006 Oct 13;349(1):162-6. Epub 2006 Aug 14.

PMID:
16930553

Supplemental Content

Support Center